Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Megiorni, Francesca ^a   Cialfi, Samantha ^a,b   McDowell, Heather P ^a,c,d   Felsani, Armando ^e   Camero, Simona ^a   Guffanti, Alessandro ^e   Pizer, Barry ^c   Clerico, Anna ^a   De Grazia, Alessandra ^a   Pizzuti, Antonio ^a   Moles, Anna ^e   Dominici, Carlo ^a,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e Genomnia   (Italy)

Author keywords

5 aza 2' deoxycytidine; Deep sequencing; MicroRNAs; MiR 378a 3p; Rhabdomyosarcoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BIOLOGICAL MARKER; DESMIN; MICRORNA; MICRORNA 133A; MICRORNA 378; MICRORNA 378A; MICRORNA 483; MICRORNA 503; MYOD1 PROTEIN; PROTEIN KINASE B; PROTEIN MYHC; PROTEIN MYOR; SOMATOMEDIN C RECEPTOR; TRANSCRIPTOME; UNCLASSIFIED DRUG; IGF1R PROTEIN, HUMAN; MIRN378 MICRORNA, HUMAN; SOMATOMEDIN RECEPTOR;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL MIGRATION ASSAY; CELL STRUCTURE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CPG ISLAND; CYTOFLUOROMETRY; CYTOSKELETON ORGANIZATION; DEEP SEQUENCING; DISEASE ASSOCIATION; DNA METHYLATION; DOWN REGULATION; EMBRYONAL RHABDOMYOSARCOMA; ENZYME PHOSPHORYLATION; EPIGENETICS; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MOLECULAR BIOLOGY; MTT ASSAY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; RNA ANALYSIS; RNA SEQUENCE; SEQUENCE HOMOLOGY; UPREGULATION; WESTERN BLOTTING; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MOLECULAR GENETICS; MUSCLE DEVELOPMENT; NUCLEOTIDE SEQUENCE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; TUMOR CELL LINE;

APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; MUSCLE DEVELOPMENT; RECEPTORS, SOMATOMEDIN; RHABDOMYOSARCOMA; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, RNA;

EID: 84924345678     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-880     Document Type: Article

References (69)

1. McDowell HP: Update on childhood rhabdomyosarcoma. Arch Dis Child 2003,88(4):354-357. 10.1136/adc.88.4.354
2. Harms D: New entities, concepts, and questions in childhood tumor pathology. Gen Diagn Pathol 1995,141(1):1-14.
3. Merlino G, Helman LJ: Rhabdomyosarcoma: working out the pathways. Oncogene 1999,18(38):5340-5348. 10.1038/sj.onc.1203038
4. Smith AC, Squire JA, Thorner P, Zielenska M, Shuman C, Grant R, Chitayat D, Nishikawa JL, Weksberg R: Association of alveolar rhabdomyosarcoma with the Beckwith-Wiedemann syndrome. Pediatr Dev Pathol 2001,4(6):550-558. 10.1007/s10024001-0110-6
5. Yang P, Grufferman S, Khoury MJ, Schwartz AG, Kowalski J, Ruymann FB, Maurer HM: Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet Epidemiol 1995,12(5):467-474. 10.1002/gepi.1370120504
6. Trahair T, Andrews L, Cohn RJ: Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma. Pediatr Blood Cancer 2007,48(3):345-348. 10.1002/pbc.20795
7. Barr FG: Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001,20(40):5736-5746. 10.1038/sj.onc.1204599
8. Lagutina I, Conway SJ, Sublett J, Grosveld GC: Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol Cell Biol 2002, 22:7204-7216. 10.1128/MCB.22.20.7204-7216.2002
9. Galindo RL, Allport JA, Olson EN: A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc Natl Acad Sci U S A 2006, 103:13439-13444. 10.1073/pnas.0605926103
10. Xia SJ, Pressey JG, Barr FG: Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002,1(2):97-104. 10.4161/cbt.51
11. Armeanu-Ebinger S, Herrmann D, Bonin M, Leuschner I, Warmann SW, Fuchs J, Seitz G: Differential expression of miRNAs in rhabdomyosarcoma and malignant rhabdoid tumor. Exp Cell Res 2012,318(20):2567-2577. 10.1016/j.yexcr.2012.07.015
12. Novak J, Vinklarek J, Vasku JB, Slaby O: MicroRNAs involved in skeletal muscle development and their roles in rhabdomyosarcoma pathogenesis. Pediatr Blood Cancer 2013,60(11):1739-1746. 10.1002/pbc.24664
13. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006,20(5):515-524. 10.1101/gad.1399806
14. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009,11(3):228-234. 10.1038/ncb0309-228
15. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004,116(2):281-297. 10.1016/S0092-8674(04)00045-5
16. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005,120(1):15-20. 10.1016/j.cell.2004.12.035
17. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature 2005,435(7043):834-838.
18. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006,6(11):857-866. 10.1038/nrc1997
19. Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, Cheuk AT, Smith MA, Houghton P, Morton C, Khan J: microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009,15(17):5560-5568. 10.1158/1078-0432.CCR-08-3287
20. Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO, Heinrich MC, Corless CL, Fire AZ, van de Rijn M: MicroRNA expression signature of human sarcomas. Oncogene 2008,27(14):2015-2026. 10.1038/sj.onc.1210836
21. Missiaglia E, Shepherd CJ, Patel S, Thway K, Pierron G, Pritchard-Jones K, Renard M, Sciot R, Rao P, Oberlin O, Delattre O, Shipley J: MicroRNA-206 expression levels correlate with clinical behavior of rhabdomyosarcomas. Br J Cancer 2010,102(12):1769-1777. 10.1038/sj.bjc.6605684
22. Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, Tuschl T, Ponzetto C: The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009,119(8):2366-2378.
23. Sun MM, Li JF, Guo LL, Xiao HT, Dong L, Wang F, Huang FB, Cao D, Qin T, Yin XH, Li JM, Wang SL: TGF-β1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma. Oncogene in press
24. Huang HJ, Liu J, Hua H, Li SE, Zhao J, Yue S, Yu TT, Jin YC, Cheng SY: MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis. Oncotarget 2014,5(8):2161-2175.
25. Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004,429(6990):457-463. 10.1038/nature02625
26. Jones PA: DNA methylation and cancer. Oncogene 2002,21(35):5358-5360. 10.1038/sj.onc.1205597
27. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Git A, Spiteri I, Das PP, Caldas C, Miska E, Esteller M: Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007,67(7):1424-1429.
28. Diao Y, Guo X, Jiang L, Wang G, Zhang C, Wan J, Jin Y, Wu Z: miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma. J Biol Chem 2014, 289:529-539. 10.1074/jbc. M113.494716
29. Maurer HM, Crist W, Lawrence W, Ragab AH, Beverly Raney R, Webber B, Wharam M, Vietti TJ, Beltangady M, Gehan EA, Hammond D, Hays DM, Heyn R, Newton W, Ortega J, Ruymann FB, Soule E, Tefft M: The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988,61(2):209-220. 10.1002/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L
30. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: tools for microRNA genomics. Nucleic Acids Res 2008,36(Database issue):D154-D158.
31. Robinson MD, Oshlack A: A scaling normalization method for differential expression analysis of RNA-seqdata. Genome Biol 2010,11(3):R25. 10.1186/gb-2010-11-3-r25
32. Robinson MD, Smyth GK: Small-sample estimation of negative binomial dispersion, with applications to SAGE data. Biostatistics 2008,9(2):321-332.
33. Dweep H, Sticht C, Pandey P, Gretz N: miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011,44(5):839-847. 10.1016/j.jbi.2011.05.002
34. Wu G, Feng X, Stein L: A human functional protein interaction network and its application to cancer data analysis. Genome Biol 2010,11(5):R53. 10.1186/gb-2010-11-5-r53
35. Wang J, Huang Q, Liu ZP, Wang Y, Wu LY, Chen L, Zhang XS: NOA: a novel network ontology analysis method. Nucleic Acids Res 2011,39(13):e87. 10.1093/nar/gkr251
36. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J, Lodish HF: Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 2010,24(9):3427-3437. 10.1096/fj.09-150698
37. Hou X, Tang Z, Liu H, Wang N, Ju H, Li K: Discovery of MicroRNAs associated with myogenesis by deep sequencing of serial developmental skeletal muscles in pigs. PLoS One 2012,7(12):e52123. 10.1371/journal.pone.0052123
38. LeRoith D, Werner H, Neuenschwander S, Kalebic T, Helman LJ: The role of the insulin-like growth factor-I receptor in cancer. Ann N Y Acad Sci 1995, 766:402-408. 10.1111/j.1749-6632.1995.tb26689.x
39. Knezevic I, Patel A, Sundaresan NR, Gupta MP, Solaro RJ, Nagalingam RS, Gupta M: A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. J Biol Chem 2012,287(16):12913-12926. 10.1074/jbc. M111.331751
40. Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, Leierseder S, Loyer X, Giacca M, Zentilin L, Thum T, Laggerbauer B, Engelhardt S: MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 2013,127(21):2097-2106. 10.1161/CIRCULATIONAHA.112.000882
41. Li H, Dai S, Zhen T, Shi H, Zhang F, Yang Y, Kang L, Liang Y, Han A: Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer. Eur J Cancer 2014,50(6):1207-1221. 10.1016/j.ejca.2013.12.010
42. McDowell HP, Foot AB, Ellershaw C, Machin D, Giraud C, Bergeron C: Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer 2010,46(9):1588-1595. 10.1016/j.ejca.2010.02.051
43. Fabbri M: MicroRNAs and cancer: towards a personalized medicine. Curr Mol Med 2013,13(5):751-756. 10.2174/1566524011313050006
44. Tan S, Wu Y, Zhang CY, Li J: Potential MicroRNA targets for cancer chemotherapy. Curr Med Chem 2013,20(29):3574-3581. 10.2174/0929867311320290003
45. Li L, Sarver AL, Alamgir S, Subramanian S: Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Lab Invest 2012,92(4):571-583.
46. Chen LT, Xu SD, Xu H, Zhang JF, Ning JF, Wang SF: MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumorangiogenesis. Med Oncol 2012,29(3):1673-1680. 10.1007/s12032-011-0083-x
47. Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, Yu X, Xia T, Cui L, Guo J: MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 2013,518(2):351-359. 10.1016/j.gene.2012.12.103
48. Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, Tognon M, Picci P, Benassi MS: miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol 2013,42(2):667-675.
49. Eichner LJ, Perry MC, Dufour CR, Bertos N, Park M, St-Pierre J, Giguere V: miR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1/ERR transcriptional pathway. Cell Metab 2010,12(4):352-361.
50. Carrer M, Liu N, Grueter CE, Williams AH, Frisard MI, Hulver MW, Bassel-Duby R, Olson EN: Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378*. Proc Natl Acad Sci U S A 2012,109(38):15330-15335. 10.1073/pnas.1207605109
51. Huang MB, Xu H, Xie SJ, Zhou H, Qu LH: Insulin-like growth factor-1 receptor is regulated by microRNA-133 during skeletal myogenesis. PLoS One 2011,6(12):e29173. 10.1371/journal.pone.0029173
52. Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA: Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One 2013,8(5):e61015. 10.1371/journal.pone.0061015
53. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB, Zhang Y: MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006, 1:e116. 10.1371/journal.pone.0000116
54. Martins AS, Olmos D, Missiaglia E, Shipley J: Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma 2011, 2011:209736.
55. Lollini PL, De Giovanni C, Landuzzi L, Nicoletti G, Scotlandi K, Nanni P: Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells. Invasion Metastasis 1991,11(2):116-124.
56. Burattini S, Ferri P, Battistelli M, Curci R, Luchetti F, Falcieri E: C2C12 murine myoblasts as a model of skeletal muscle development: morpho-functional characterization. Eur J Histochem 2004,48(3):223-233.
57. Gagan J, Dey BK, Layer R, Yan Z, Dutta A: MicroRNA-378 targets the myogenic repressor MyoR during myoblast differentiation. J Biol Chem 2011,286(22):19431-19438. 10.1074/jbc. M111.219006
58. Elia L, Contu R, Quintavalle M, Varrone F, Chimenti C, Russo MA, Cimino V, De Marinis L, Frustaci A, Catalucci D, Condorelli G: Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 2009,120(23):2377-2385. 10.1161/CIRCULATIONAHA.109.879429
59. Monteys AM, Spengler RM, Wan J, Tecedor L, Lennox KA, Xing Y, Davidson BL: Structure and activity of putative intronic miRNA promoters. RNA 2010,16(3):495-505. 10.1261/rna.1731910
60. Li Z, Gu X, Fang Y, Xiang J, Chen Z: microRNA expression profiles in human colorectal cancers with brain metastases. Oncol Lett 2012,3(2):346-350.
61. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F: MicroRNA expression profiling of oral carcinoma identifies new markers of tumorprogression. Int J Immunopathol Pharmacol 2010,23(4):1229-1234.
62. Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, Schübeler D: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007,39(4):457-466. 10.1038/ng1990
63. Ayton PM, Chen EH, Cleary ML: Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol 2004, 24:10470-10478. 10.1128/MCB.24.23.10470-10478.2004
64. Gastaldi T, Bonvini P, Sartori F, Marrone A, Iolascon A, Rosolen A: Plakoglobin is differentially expressed in alveolar and embryonalrhabdomyosarcoma and is regulated by DNA methylation and histone acetylation. Carcinogenesis 2006,27(9):1758-1767. 10.1093/carcin/bgl008
65. Wolf S, Hagl B, Kappler R: Identification of BMP2 as an epigenetically silenced growth inhibitor in rhabdomyosarcoma. Int J Oncol 2014,44(5):1727-1735.
66. Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001,134(7):573-586. 10.7326/0003-4819-134-7-200104030-00011
67. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010,28(4):562-569. 10.1200/JCO.2009.23.8329
68. Hurtubise A, Bernstein ML, Momparler RL: Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int 2008, 8:16.
69. Cote GM, Choy E: Role of Epigenetic Modulation for the Treatment of Sarcoma. Curr Treat Options Oncol 2013,14(3):454-464. 10.1007/s11864-013-0239-3